Trial Profile
A Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel Group, Dose-finding, Pivotal, Phase 2b/3 Study to Evaluate the Efficacy, Safety, and Tolerability of Intravenous BYM338 at 52 Weeks on Physical Function, Muscle Strength, and Mobility and Additional Long Term Safety up to 2 Years in Patients With Sporadic Inclusion Body Myositis
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Bimagrumab (Primary)
- Indications Inclusion body myositis
- Focus Registrational; Therapeutic Use
- Acronyms RESILIENT
- Sponsors Novartis
- 28 Apr 2017 Results presented at the 69th Annual Meeting of the American Academy of Neurology
- 16 Nov 2016 Results presented at the 80th American College of Rheumatology and the 51st Annual Meeting of the Association of Rheumatology and Health Professionals
- 21 Apr 2016 Primary endpoint has not been met. (Change from Baseline in 6 Minute Walking Distance Test (6MWD) meters to , as per Morphosys media release.